Rakuten Investment Management Inc. Acquires Shares of 243,100 Boston Scientific Corporation $BSX

Rakuten Investment Management Inc. purchased a new stake in Boston Scientific Corporation (NYSE:BSX) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 243,100 shares of the medical equipment provider’s stock, valued at approximately $10,570,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Brighton Jones LLC increased its holdings in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. FWL Investment Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth $26,000. Main Street Financial Solutions LLC boosted its position in Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after buying an additional 1,971 shares during the last quarter. Ieq Capital LLC boosted its position in Boston Scientific by 97.0% in the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after buying an additional 60,860 shares during the last quarter. Finally, HUB Investment Partners LLC increased its stake in shares of Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after buying an additional 2,556 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity

In other news, Director David C. Habiger bought 2,100 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Michael F. Mahoney acquired 186,240 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on BSX shares. Piper Sandler reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Boston Scientific in a research note on Friday, June 12th. Zacks Research downgraded shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Wolfe Research cut shares of Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. Jefferies Financial Group lowered their target price on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday, June 24th. Finally, Evercore set a $65.00 price target on Boston Scientific in a research note on Monday, July 6th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $46.82 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The firm has a market cap of $67.85 billion, a price-to-earnings ratio of 18.96, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56. The stock’s 50-day moving average is $46.56 and its 200-day moving average is $56.65. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the prior year, the company posted $0.75 earnings per share. The firm’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a stock repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.